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Zusammenfassung
Aktuelle Studien deuten darauf hin, dass Adipositas und 
ein Mangel an körperlicher Aktivität nicht nur mit einem er-
höhten Risiko assoziiert sind, an einem Mammakarzinom 
zu erkranken, sondern auch nach der Erkrankung mit einer 
gesteigerten Rezidivrate und Mortalität einhergehen. Die 
SUCCESS C-Studie ist die erste europäische Studie, die 
den Einfluss eines intensivierten Lebensstilinterventions-
programms auf das krankheitsfreie Überleben von Frauen 
mit frühem Mammakarzinom untersucht. Außerdem wer-
den ausgewählte Biomarker getestet. Insgesamt werden 
3.547 Frauen mit frühem, Her2/neu-negativen Mammakar-
zinom eingeschlossen. In der ersten Randomisation wird 
das krankheitsfreie Überleben unter einer Therapie mit ent-
weder 3 Zyklen FEC (Epirubicin, Fluorouracil, Cyclophos-
phamid), gefolgt von 3 Zyklen Docetaxel oder 6 Zyklen 
Docetaxel-Cyclophosphamid verglichen, und da mit die 
Rolle einer anthrazyklinfreien Chemotherapie in diesem 
Kollektiv geprüft. Die zweite Randomisation vergleicht das 
krankheitsfreie Überleben von Patientinnen mit einem 
Body Mass Index von 24–40 kg/m2, die entweder ein tele-
fonbasiertes Lebensstilinterventionsprogramm mit dem 
Ziel einer moderaten Gewichtsabnahme oder lediglich all-
gemeine Informationen für eine gesunde Lebensführung 
erhalten. Zusätzlich zur klinischen Fragestellung werden 
brustkrebs- oder adipositasassoziierte Biomarker auf ihre 
prognostische und prädiktive Wertigkeit hin geprüft. Die 
SUCCESS C-Studie wird wertvolle Informationen zur Effek-
tivität eines Lebensstilinterventionsprogramms zur Progno-
severbesserung bei Mammakarzinompatientinnen liefern.
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Summary
Cohort trials have shown evidence that obesity and a low 
level of physical activity are not only associated with a 
higher risk of developing breast cancer, but also with an 
increased risk for recurrence and reduced survival in 
breast cancer patients. The SUCCESS C study is the first 
European trial to evaluate the effect of an intensive life-
style intervention program on disease-free survival in 
women with early breast cancer and to examine the 
 predictive value of selected biomarker candidates. A total 
of 3,547 women with early-stage, Her2/neu-negative 
breast cancer will be included. The first randomization will 
compare disease-free survival in patients treated with 
 either 3 cycles of FEC (epirubicine, fluorouracil, cyclophos-
phamide), followed by 3 cycles of docetaxel or 6 cycles of 
docetaxel-cyclophosphamide, and thus assess the role of 
anthracycline-free chemotherapy. The second randomiza-
tion compares disease-free survival in patients with a 
body mass index of 24–40 kg/m2 receiving either a tele-
phone-based individualized lifestyle intervention program 
aiming at moderate weight loss or general recommenda-
tions for a healthy lifestyle alone. In addition, the study 
will evaluate the predictive role of cancer-associated and 
obesity-related biomarkers for the prediction of disease 
recurrence and survival. This SUCCESS C trial will provide 
valuable information on the effects of a lifestyle interven-
tion program on the prognosis of early breast cancer 
patients.
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cancer (RR 0.69; 95% CI 0.48–0.98; p = 0.04). This risk re-
duction was observed for estrogen receptor (ER)-negative 
(p = 0.003) but not ER-positive (p = 0.53) invasive breast 
cancer. 
Physical activity seems also to protect women who were 
 already diagnosed with breast cancer. The Nurses’ Health 
Study, a prospective observational study, evaluated the role of 
physical activity for disease recurrence and mortality [7]. 
Physical activity in this trial was measured as metabolic 
 equivalent task (MET) hours per week with 3 MET hours 
being equivalent to 1 h of walking at 3–5 km/h. Compared 
with women who engaged in less than 3 MET hours per week, 
the adjusted relative risk of death from breast cancer was 0.80 
(95% CI 0.60–1.06) for 3–8.9 MET hours per week, 0.50 (95% 
CI 0.31–0.82) for 9–14.9 MET hours per week, 0.56 (95% CI 
0.38–0.84) for 15–23.9 MET hours per week, and 0.60 (95% 
CI 0.40–0.89) for 24 or more MET hours per week (p = 0.004). 
The benefit of physical activity was particularly apparent 
among women with hormone-responsive tumors, and reduc-
tion in mortality highest with 6% at 10 years for women who 
were physically active for 3–5 h a week.
The Influence of Nutrition on Breast Cancer
While only observational studies are available on physical 
 activity, two prospectively randomized trials have been pub-
lished on nutrition-based lifestyle intervention. Chlebowski 
et al. [8] reported the results of the Women’s Intervention 
Nutrition Study (WINS). In this randomized controlled inter-
vention study, postmenopausal women with early stage breast 
cancer were advised to reduce dietary fat intake to approxi-
mately 15–20% of their total energy intake. Women in the 
 dietary intervention group successfully lowered fat intake 
(33.3 vs. 51.3% in the control group), but also showed signifi-
cant weight loss compared to the control group (relative dif-
ference of 2.3 kg at year 1 and 2.7 kg at year 5, p < 0.05). The 
hazard ratio for cancer recurrence in the intervention vs. the 
control group was 0.76 (95% CI 0.60–0.98; p = 0.034). The 
lifestyle intervention tended to have a greater effect on 
women with hormone receptor-negative breast cancer (haz-
ard ratio (HR) = 0.58; 95% CI 0.37–0.91), but there was also a 
modest benefit for those with hormone receptor-positive 
breast cancer (HR = 0.85; 95% CI 0.63–1.14).
In the Women’s Healthy Eating and Living (WHEL) trial, 
women with early-stage breast cancer were randomized to re-
ceive active intervention consisting of a reduction in fat intake 
to 15–20% (total fat intake) and an increased intake of vege-
tables and fruit compared to a control group without interven-
tion. After a mean follow-up of 7.3 years, there was no differ-
ence in recurrent breast cancer events and death indicating 
that a diet that was very high in vegetables, fruit and fiber and 
low in fat does not reduce breast cancer events or mortality. 
In contrast to the WINS trial, there was a modest increase in 
Introduction
Breast cancer is the most frequent malignancy in women 
of the industrialized Western hemisphere. In 2008, it was 
 estimated that worldwide 1.38 million women were diagnosed 
with breast cancer, accounting for around a 10th (10.9%) of 
all new cancers and nearly a quarter (23%) of all female can-
cer cases [1]. In recent years, a decrease in mortality has been 
observed, which is attributed to early detection through 
screening programs and improved treatment efficacy. How-
ever, breast cancer incidence has been increasing for many 
years in economically developed countries. A substantial pro-
portion of these breast cancers are thought to be associated 
with internal and external estrogen exposure, related to age at 
menarche and menopause, parity, duration of breastfeeding, 
and use of contraceptives and hormone replacement therapy. 
In addition to these well known risk factors, there is growing 
evidence for the influence of non-reproductive lifestyle fac-
tors. Several cohort studies have shown an increased risk for 
breast cancer associated with obesity, alcohol consumption, 
and low physical activity. Large prospective epidemiological 
studies show an association between obesity and breast can-
cer. In the Million Women Study, increasing body mass index 
(BMI) was associated with a significant increase in the risk of 
several cancer types, among them endometrial cancer, adeno-
carcinoma of the esophagus, kidney cancer, breast cancer in 
postmenopausal women, and colorectal cancer in premeno-
pausal women [2]. Overweight postmenopausal women were 
observed to have a 10–20% increased risk of breast cancer, 
and obese postmenopausal women a 30% increased risk, 
while obese premenopausal women show a 20% risk reduc-
tion. In contrast, obesity is associated with poor prognosis 
both in pre- and postmenopausal breast cancer patients [3, 4]. 
Changes in hormone metabolism, especially higher levels of 
circulating estrogens through increased aromatase activation, 
are thought to be one major cause of carcinogenesis. How-
ever, other obesity-related factors including insulin, adipo-
cytokines such as leptin and adiponectin, as well as inflamma-
tory markers such as C-reactive protein and interleukins may 
contribute [5]. 
The Role of Physical Activity in Breast Cancer
Several mostly observational studies have evaluated the influ-
ence of lifestyle intervention on carcinogenesis and preven-
tion of recurrence and mortality. A total of 110,599 women 
aged between 20 and 79 years were followed in the California 
Teachers Study [6]. A protective role of physical activity 
against invasive and in situ breast cancer is supported by this 
trial. Women who reported long-term strenuous activity of 
more than 5 h per week had a significantly reduced risk for 
both invasive breast cancer (relative risk (RR) 0.80; 95% con-
fidence interval (CI) 0.69–0.94; p = 0.02), and in situ breast 
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the role of anthracyclines, leading to late-onset cardiac dys-
function and heart failure beside the immediate toxicity asso-
ciated with cardiac and hematologic effects. Especially in view 
of new targeted agents being implemented into clinical treat-
ment protocols, cardiotoxicity is regarded as a relevant issue 
due to diminished cardiac recovery observed with these 
agents.
In 2006, Slamon et al. [17] presented a retrospective analy-
sis based on BCIRG 006 data showing that the benefit of ad-
juvant anthracycline therapy is limited to those patients who 
are Her2/neu-positve, and in particular to patients with co-
amplification of the Her2/neu gene and the topoisomerase 
2 alpha gene. Another more recent analysis by Gennari et al. 
[18] confirmed these findings after pooling data from 8 studies 
and comparing non-anthracycline-based adjuvant chemo-
therapy (mainly CMF) with anthracycline-containing combi-
nations. For Her2/neu-positive tumors (29%, n = 1,536), 
 anthracycline-based regimens were superior to non-anthra-
cycline-based regimens in terms of disease-free survival and 
overall survival (HR of relapse 0.71 and death 0.73). For 
Her2/neu-negative tumors (remaining 3,818 patients), anthra-
cyclines did not improve disease-free survival and overall 
 survival (HR = 1.0; HR = 1.03, respectively) (fig. 2). Based on 
a retrospective analysis of the MA 05 trial testing CMF versus 
Canadian FEC in 710 node-positive (N+) premenopausal 
body weight in both groups (0.7 kg in the intervention group 
vs. 0.3 kg in the control group at year 6) and there was only a 
modest decrease in fat intake in the intervention group 
(28.5% at baseline, 22.7% at year 1, and 28.9% at year 6) [9].
The SUCCESS C Study
The lack of data in the field of lifestyle intervention warrants 
further investigation of the effect of diet and physical activity 
on the prognosis of breast cancer patients. In 2009, the SUC-
CESS Study Group therefore initiated the SUCCESS C trial, 
to our knowledge the only recruiting trial evaluating a life-
style intervention program. The aim of the trial was to evalu-
ate the role of anthracycline-free chemotherapy treatment in 
a Her2/neu-negative breast cancer patient population. The 
second randomization addresses the role of lifestyle inter-
vention on the prognosis of early breast cancer patients. 
 SUCCESS C is a German multicenter, 2×2 factorial design, 
randomized phase III study comparing disease-free survival 
after randomization in patients treated with 3 cycles of FEC 
(epirubicine, fluorouracil, cyclophosphamide) chemotherapy, 
followed by 3 cycles of docetaxel (D) versus 6 cycles of 
docetaxel-cyclophosphamide (DC), and to compare the dis-
ease-free survival in patients with a BMI of 24–40 kg/m2 after 
randomization to with vs. without intensive lifestyle interven-
tion. Patients will be required to have histopathological proof 
of a Her2/neu-negative tumor and: axillary lymph node me-
tastases (pN1–3) or high-risk node-negative (defined as pT≥2 
or histopathological grade 3 or age ≤ 35 or negative hormone 
receptor status), but are not allowed to have evidence of dis-
tant disease. In addition to the treatment intervention, the 
translational research program of the trial tries to identify 
prognostic and predictive markers that can be used to further 
individualize therapy in early breast cancer (fig. 1).
Anthracycline-Based Chemotherapy Treatment in Early 
Breast Cancer
For patients with an increased risk for recurrence, several 
 randomized studies and the 2000 Oxford overview confirm 
that anthracycline-based chemotherapy offers a significant 
survival benefit compared with CMF (cyclophosphamide, 
methotrexate, 5-fluorouracil) [10–13]. The meta-analysis of 
the Early Breast Cancer Trialists’ Collaborative Group 
 estimates a recurrence-free survival benefit of 3.2% and an 
overall survival benefit of 2.7% for anthracycline-based 
 multiagent chemotherapy compared to CMF [14].
However, the role of antracyclines in adjuvant breast can-
cer treatment has been increasingly questioned with regard to 
an appropriate risk-benefit evaluation within the last years 
[15, 16]. It is particularly the late and life-threatening cardio-
toxicity that remains clinically important and compromises 
Fig. 1. SUCCESS C study design.
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The Lifestyle Intervention Program within SUCCESS C
The second objective of the study will be to evaluate the effi-
cacy of a lifestyle intervention program to improve disease-
free survival in early breast cancer. Patients with a BMI of 
24–40 kg/m2 at the time of enrollment will be subsequently 
randomized to a lifestyle intervention program versus obser-
vation. Women randomized to the intervention arm will re-
ceive a standardized individualized intervention program for 
the duration of 2 years designed to promote weight loss over 
the first 6 months followed by weight loss maintenance. The 
predefined treatment goals are: i) weight loss of 5–10% of 
baseline weight but not below a BMI of 22 kg/m2, at least 5% 
in those with a BMI between 24 and 30 kg/m2, and 10% in 
those with a BMI ≥ 30 kg/m2; ii) caloric deficit of 500–1,000 
kcal/day based on current weight and weight loss goals; iii) fat 
intake of less than 20–25% of the total energy intake; iv) pro-
gressive physical activity depending on baseline activity; grad-
ual increase to 150–200 min of moderate physical activity per 
week; pedometers will be distributed to support the intended 
step-wise increase in physical activity.
The key elements of the intervention are the following: 
i) A hypocaloric diet with an estimated energy deficit of 500–
1,000 kcal/day which is mainly based on fat reduction to 20–
25% of the total energy intake. In parallel, the intake of 
 wholegrain products, fruit and vegetables should be increased. 
The level of caloric intake will be between 1,200 and 1,800 
kcal/day according to the individual goals. Adaptations are 
possible during the course of the intervention to achieve the 
weight goals. ii) A gradual increase in physical activity. The 
preferred recommendation is a moderate intensity aerobic 
physical activity such as brisk walking between 150 and 200 
min per week, coupled with resistance and stretching exer-
cises. iii) Individual lessons in behavioral and motivational 
 issues including relapse prevention, reduction in emotional 
distress, overcoming barriers.
The intervention will be provided by a personal lifestyle 
coach working in a central call center. This coaching team 
consists of trained nurses, dieticians, physicians, and psycholo-
gists. A series of semi-structured telephone calls will build the 
core of the active intervention, supplemented with a detailed 
participant workbook and regular newsletters. Women will be 
encouraged to start with the diet and the increase in physical 
activity as quickly as possible to reach their weight loss goal 
within 6 months and then, to maintain this weight loss. 
As weight loss is the main goal of the life style intervention, 
normal weight or underweight patients (BMI < 24) are 
 excluded from this randomization. In these patients, further 
weight loss might even have a negative effect on their general 
health as well as on breast cancer prognosis. On the other 
hand, extreme obesity in overweight patients with a BMI > 40 
is associated with an increased risk of chronic diseases, and 
these women were not thought to be able to participate in our 
telephone-based intervention program. Patients randomized 
 patients, clinical routine Her2/neu status determination is 
being regarded as a good predictor of an anthracycline re-
sponse [19]. These results suggest that Her2/neu-negative 
 patients might have only limited benefit from anthracycline-
based chemotherapy, especially in view of the cardiac side 
 effects. Thus it seems crucial to identify those subgroups of 
breast cancer patients in which the expected benefits are most 
likely to outweigh known risks, and confine anthracycline 
treatment to these. 
Further support for anthracycline-free adjuvant chemo-
therapy comes from a randomized phase III trial by Jones et 
al. [20] for the US Oncology Group. A total of 1,016 high-risk 
node-negative (N–) and N+ breast cancer patients received 
either 4 cycles of doxorubicin (60 mg/m2) plus cyclophospha-
mide (600 mg/m2) (AC) every 3 weeks (q3w) or 4 cycles of 
docetaxel (75 mg/m2) plus cyclophosphamide (600 mg/m2) 
(TC) q3w. The results were in favor of TC, showing disease-
free survival of 86 vs. 80% (p = 0.01) and overall survival of 
90 vs. 87% (p = 0.13). The update with an extended 7-year 
follow-up further supports the advantage of TC with a dis-
ease-free survival of 81 vs. 75% (p = 0.033) and overall sur-
vival of 87 vs. 82% (p = 0.032) [21]. Despite this promising 
 results, 4 cycles of AC can not be accepted as adequately 
dosed standard treatment in early breast cancer. The evalua-
tion of anthracycline-free regimens against modern sequential 
anthracycline-taxane-based regimens in several open trials 
 reflects the interest in this clinically relevant question. In the 
German Plan B trial, 6 cycles of TC are tested against 4 cycles 
of EC followed by 4 cycles of docetaxel. The SUCCESS C 
trial will compare the disease-free survival after randomiza-
tion in patients treated with 3 cycles of FEC (epirubicine 
100 mg/m2 + fluorouracil 500 mg/m2 + cyclophosphamide 
500 mg/m2), followed by 3 cycles of D (docetaxel 100 mg/mg2) 
versus 6 cycles of DC (cyclophosphamide 600 mg/m2 q3w + 
docetaxel 75 mg/m2).
Fig. 2. Meta-analysis of anthracycline-efficacy in relation to HER2/neu 
status.
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tive, postmenopausal patients will be entered into a treatment 
substudy, randomizing between tamoxifen for 2–3 years fol-
lowed by exemestane (early switch) vs. exemestane upfront. 
All patients will be followed with a subsequent blood test 
after 2 years and, if applicable, in the case of recurrence 
(fig. 3). This subprotocol of the Success C trial will provide 
additional information on whether CTCs can be used as a 
prognostic factor for an adverse outcome as well as a predic-
tive marker for endocrine treatment efficacy. 
Conclusion
There is conclusive epidemiological data suggesting an impor-
tant role of obesity and lifestyle factors on carcinogenesis and 
survival after breast cancer diagnosis. The prospectively rand-
omized SUCCESS C trial will provide information on whether 
lifestyle modification focusing on a fat-reduced healthy diet 
and moderate physical activity is able to improve the progno-
sis of breast cancer patients. Additionally, the efficacy of an-
thracycline-free treatment regimen in Her2/neu-negative 
breast cancer patients will be evaluated. The translational re-
search program of the trial will aim to identify prognostic and 
predictive markers which can help to further individualize 
breast cancer treatment. 
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to the control arm or with a BMI < 24 kg/m2 or > 40 kg/m2 will 
be mailed information on general health after completion of 
chemotherapy and at 1 year. Participants in the control group 
will additionally receive a 2-year free subscription to a life-
style magazin.
Translational Research Program
The aim of the translational research program is to identify 
prognostic and predictive markers that can be used to further 
individualize therapy in early breast cancer. It is planned to 
measure obesity-related biomarkers like fasting insulin and 
adiponectin and potentially other upcoming adipokines of in-
terest to test the prognostic and predictive value of these 
markers in the context of the intervention program. Addition-
ally, genetic variations in germline DNA and tumor DNA will 
be compared with the phenotype of the tumor and the effi-
cacy and side effects of chemotherapy. This should result in a 
biomarker panel which comprises the patients’ DNA and 
tumor material to individualize the choice for or against a 
therapy with anthracyclines. 
The detection of circulating tumor cells (CTCs) in the 
 peripheral blood will also be an integral part of the research 
program. Based on the promising results of the predecessor 
trial, the SUCCESS A trial, which indicated a prognostic 
 relevance of CTCs [22], an endocrine treatment randomiza-
tion will be performed. CTC-positive, hormone receptor-posi-
Postmenopausal women without 
Circulating Tumour Cells:
AI qid p.o.x 5 a
Postmenopausal women with 
 Circulating Tumour Cells:
Random assignment to upfront 
 Exemestane qid p.o.x 5 a vs.
Tamoxifen 20mg qid p.o.x 2 a then 
switch to Exemestane qid p.o.x 3 a
Fig. 3. Endocrine treatment for postmenopausal hormone receptor-
positive women.
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